» Articles » PMID: 20472344

Impact of Bone Marrow Radiation Dose on Acute Hematologic Toxicity in Cervical Cancer: Principal Component Analysis on High Dimensional Data

Overview
Specialties Oncology
Radiology
Date 2010 May 18
PMID 20472344
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To study the effects of increasing pelvic bone marrow (BM) radiation dose on acute hematologic toxicity in patients undergoing chemoradiotherapy, using a novel modeling approach to preserve the local spatial dose information.

Methods And Materials: The study included 37 cervical cancer patients treated with concurrent weekly cisplatin and pelvic radiation therapy. The white blood cell count nadir during treatment was used as the indicator for acute hematologic toxicity. Pelvic BM radiation dose distributions were standardized across patients by registering the pelvic BM volumes to a common template, followed by dose remapping using deformable image registration, resulting in a dose array. Principal component (PC) analysis was applied to the dose array, and the significant eigenvectors were identified by linear regression on the PCs. The coefficients for PC regression and significant eigenvectors were represented in three dimensions to identify critical BM subregions where dose accumulation is associated with hematologic toxicity.

Results: We identified five PCs associated with acute hematologic toxicity. PC analysis regression modeling explained a high proportion of the variation in acute hematologicity (adjusted R(2), 0.49). Three-dimensional rendering of a linear combination of the significant eigenvectors revealed patterns consistent with anatomical distributions of hematopoietically active BM.

Conclusions: We have developed a novel approach that preserves spatial dose information to model effects of radiation dose on toxicity, which may be useful in optimizing radiation techniques to avoid critical subregions of normal tissues. Further validation of this approach in a large cohort is ongoing.

Citing Articles

Artificial Intelligence Algorithms in Predictive Factors for Hematologic Toxicities During Concurrent Chemoradiation for Cervical Cancer.

Petre I, Negru S, Dragomir R, Bordianu A, Petre I, Marc L Cureus. 2024; 16(10):e70665.

PMID: 39493069 PMC: 11528638. DOI: 10.7759/cureus.70665.


Prevention and management of radiotherapy-related toxicities in gynecological malignancies. Position paper on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology).

Perrucci E, Macchia G, Cerrotta A, Andrulli A, Autorino R, Barcellini A Radiol Med. 2024; 129(9):1329-1351.

PMID: 39198369 PMC: 11379782. DOI: 10.1007/s11547-024-01844-5.


Acute hematologic toxicity prediction using dosimetric and radiomics features in patients with cervical cancer: does the treatment regimen matter?.

Yue H, Li X, You J, Feng P, Du Y, Wang R Front Oncol. 2024; 14:1365897.

PMID: 38835389 PMC: 11148289. DOI: 10.3389/fonc.2024.1365897.


Predictors of Acute Hematologic Toxicity in Women Receiving Extended-Field Chemoradiation for Cervical Cancer: Do Known Pelvic Radiation Bone Marrow Constraints Apply?.

Hara J, Jutzy J, Arya R, Kothari R, McCall A, Howard A Adv Radiat Oncol. 2022; 7(6):100998.

PMID: 36420189 PMC: 9677190. DOI: 10.1016/j.adro.2022.100998.


Tensor Regression-based Model to Investigate Heterogeneous Spatial Radiosensitivity After I-125 Seed Implantation for Prostate Cancer.

Kobayashi K, Murakami N, Takahashi K, Inaba K, Igaki H, Hamamoto R In Vivo. 2021; 35(1):489-497.

PMID: 33402501 PMC: 7880750. DOI: 10.21873/invivo.12283.


References
1.
. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996; 348(9034):1049-54. View

2.
Duenas-Gonzalez A, Zarba J, Patel F, Alcedo J, Beslija S, Casanova L . Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011; 29(13):1678-85. DOI: 10.1200/JCO.2009.25.9663. View

3.
Skala M, Rosewall T, Dawson L, Divanbeigi L, Lockwood G, Thomas C . Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 68(3):690-8. DOI: 10.1016/j.ijrobp.2006.12.064. View

4.
Rose B, Aydogan B, Liang Y, Yeginer M, Hasselle M, Dandekar V . Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010; 79(3):800-7. PMC: 2907446. DOI: 10.1016/j.ijrobp.2009.11.010. View

5.
Blomlie V, Rofstad E, Skjonsberg A, Tvera K, Lien H . Female pelvic bone marrow: serial MR imaging before, during, and after radiation therapy. Radiology. 1995; 194(2):537-43. DOI: 10.1148/radiology.194.2.7824737. View